Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CD74 | P04233 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9634370 | 0.85 | NOTUM (0.50) | P2RX7NOTUMMAOAL3MBTL1GLA | |
| SCHEMBL27711742 | 0.85 | P2RX7 (0.47) | P2RX7NOTUMMAOAL3MBTL1GLA | |
| SCHEMBL24785696 | 0.85 | P2RX7 (0.47) | P2RX7NOTUMMAOAL3MBTL1GLA | |
| SCHEMBL13160180 | 0.83 | NOTUM (0.51) | NOTUMESRRA | |
| SCHEMBL13183607 | 0.83 | NOTUM (0.53) | NOTUMESRRAPTGS1PTGS2 | |
| SCHEMBL19589440 | 0.83 | MAOA (0.50) | NOTUMMAOAESRRA | |
| SCHEMBL23008630 | 0.82 | CYP1B1 (0.37) | NOTUM | |
| SCHEMBL9729936 | 0.81 | FLT3 (0.46) | NOTUMMIFESRRAPTGS1PTGS2 | |
| SCHEMBL25868678 | 0.81 | RXRA (0.50) | L3MBTL1ESRRAALDH1A1 | |
| SCHEMBL25820296 | 0.81 | RXRA (0.58) | ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205206-A1 | LINCOSAMIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-05-10 | — | — | US | disclosed |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-05-14 | — | — | US | disclosed |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20160072081-A1 | Transition metal complexes with carbene ligands and the use thereof in OLEDs | BASF SE (DE) | 2016-03-10 | — | — | US | disclosed |
| US-20160072081-A1 | Transition metal complexes with carbene ligands and the use thereof in OLEDs | BASF SE (DE) | 2016-03-10 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2015007613-A1 | O-ALKYL TRIAZOLYL CARBAMATES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014177518-A1 | TRANSITION METAL COMPLEXES WITH CARBENE LIGANDS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | PNKP, PPM1A, PPM1B | P2RX7 2608/4885NOTUM 3315/4885MAOA 3566/4885 |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | P2RX7 5/4885NOTUM 4148/4885MAOA 2677/4885 |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | P2RX7 3923/4885NOTUM 807/4885MAOA 4080/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | P2RX7 5/4885NOTUM 4148/4885MAOA 2677/4885 |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | PNKP, PPM1A, PPM1B | P2RX7 2608/4885NOTUM 3315/4885MAOA 3566/4885 |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | P2RX7 4451/4885NOTUM 4663/4885MAOA 4390/4885 |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | P2RX7 2336/4885NOTUM 711/4885MAOA 69/4885 |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | TOP2A, TOP2B, TOP1 | P2RX7 3257/4885NOTUM 3217/4885MAOA 2425/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | P2RX7 1235/4885NOTUM 3099/4885MAOA 3420/4885 |
| US-20160072081-A1 | Transition metal complexes with carbene ligands and the use thereof in OLEDs | OCIAD1, OCIAD2, TRPM6 | P2RX7 3343/4885NOTUM 2349/4885MAOA 1157/4885 |
| US-10981875-B2 | Quinolone-based compounds with anticancer activity | TOP2A, TOP2B, TOP1 | P2RX7 3257/4885NOTUM 3217/4885MAOA 2425/4885 |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | P2RX7 2336/4885NOTUM 711/4885MAOA 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.